Type 2 Diabetes
10 competing products in clinical development for Type 2 Diabetes.
Pipeline by Phase
Pre-clinical3
Phase 11
Phase 21
Phase 32
Approved3
All Products (10)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| insulin lispro protamine suspension:insulin lispro rDNA origin low mix + insulin glargine | Eli Lilly | Approved | Completed | 85 |
| Lispro mix 75/25 + Glargine | Eli Lilly | Approved | Completed | 85 |
| Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos] | Celltrion | Approved | Recruiting | 85 |
| Tirzepatide + Semaglutide | Eli Lilly | Phase 3 | Completed | 77 |
| Orforglipron | Eli Lilly | Phase 3 | Completed | 77 |
| Dulaglutide + Placebo | Eli Lilly | Phase 2 | Completed | 52 |
| NEX-22A, a prolonged release formulation of liraglutide | Nanexa AB | Phase 1 | Completed | 28 |
| Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDs | Eli Lilly | Pre-clinical | Completed | 23 |
| Exenatide + Placebo | Eli Lilly | Pre-clinical | Completed | 23 |
| Dual-combination therapy + Triple-combination therapy | Celltrion | Pre-clinical | Recruiting | 23 |